

DOCUMENT NUMBER: 130:61089 ✓
 TITLE: Treatment of **diabetes** with thiazolidinedione and metformin
 INVENTOR(S): Smith, Stephen Alistair
 PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK
 SOURCE: PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857634 ✓	A1	19981223	WO 1998-EP3690	19980615 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9885393	A1	19990104	AU 1998-85393	19980615 <--
EP 996444	A1	20000503	EP 1998-936364	19980615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
BR 9810172	A	20000808	BR 1998-10172	19980615
JP 2002504137	T2	20020205	JP 1999-503755	19980615
NZ 501260	A	20020927	NZ 1998-501260	19980615
CN 1114404	B	20030716	CN 1998-806224	19980615
NZ 515554	A	20030926	NZ 1998-515554	19980615
ZA 9805238	A	20000217	ZA 1998-5238	19980617 <--
NO 9906266	A	19991217	NO 1999-6266	19991217 <--
MX 9912078	A	20000831	MX 1999-12078	19991217
BG 104060	A	20001031	BG 2000-104060	20000106
US 2002004515	A1	20020110	US 2001-925394	20010809
US 2002137772	A1	20020926	US 2002-99161	20020313
CN 1429551	A	20030716	CN 2002-156128	20021206
US 2003109553	A1	20030612	US 2003-340426	20030110

PRIORITY APPLN. INFO.:

GB 1997-12857	A	19970618
GB 1998-6706	A	19980327
NZ 1998-501260	A1	19980615
WO 1998-EP3690	W	19980615
US 1999-446030	B1	19991215
US 2001-925394	B1	20010809
US 2002-99161	B1	20020313

AB A method for the treatment and/or prophylaxis of **diabetes mellitus**, conditions assocd. with **diabetes mellitus**, and certain complications thereof, in a mammal which method comprises administering an effective nontoxic and **pharmaceutically** acceptable amt. of an insulin sensitizer rosiglitazone (I) and a biguanide antihyperglycemic agent such as metformin. Pharmacokinetics of I and metformin administered alone or in combination are described. Formulations for prepg. tablets contg. I is presented.

IT **155141-29-0**, Rosiglitazone maleate

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of **diabetes** with thiazolidinedione insulin

sensitizer and metformin)

RN 155141-29-0 HCAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 122320-73-4

CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>